MCE 免疫檢查點蛋白 Immune Checkpoint Proteins

www.MedChemEInhibitors ? ScreeningLibraries ? Proteins免疫檢查點蛋白免疫檢查點(ImmuneCheckpoints)分子是對免疫應(yīng)答發(fā)揮抑制或刺激作用的配體-受體對，它們在維持免疫穩(wěn)態(tài)和免疫耐受中起著重要的調(diào)節(jié)作用。大多數(shù)被報道的免疫檢查點蛋白在適應(yīng)性免疫系統(tǒng)（特別是T細(xì)胞）和先天免疫系統(tǒng)的細(xì)胞上表達(dá)。一些腫瘤細(xì)胞通過結(jié)合共抑制受體分子，限制正常的抗腫瘤免疫反應(yīng)，從而幫助免疫逃逸。癌癥的免疫檢查點治療策略包括了靶向這些調(diào)控途徑，以恢復(fù)免疫細(xì)胞的抗腫瘤功能。目前，研究最廣泛的抑制性免疫檢查點包括CTLA-4和PD-1/PD-L1等[7][8]。A2aRVISTAAdenosineB7-H3PDL1/PDL2A2aRGalectin-9??CD80/CD86PD1TIM-3CD80/CD86CTLA-4OX40LCD28T-CellCD40OX40CD40LB7RP1ICOSCD70CD27HVEMBTLAAPCorLAG-3TumorCellTCRMHCl/llKIRGITRGITRL4-1BBCD226/TIGIT4-1BBLCD155/CD112OtherpotentialpathwaysIL10 CD47IDO TLRTGF-β ArginaseInhibitoryPathwaysStimulatoryPathwaysFigure1.常見的免疫檢查點刺激途徑和抑制途徑[9]4MCEMasterofBioactiveMoleculesCat.No.ProductNameSpeciesSourceTagHY-P70691CTLA-4HumanMammalianCellsC-GSTHY-P70632PD-L1MouseMammalianCellsC-HisHY-P7395PD-1HumanMammalianCellsC-hFcHY-P70482TIM3HumanMammalianCellsC-HisHY-P70722LAG-3HumanMammalianCellsC-HisHY-P70624TIGITHumanMammalianCellsC-HisHY-P7327CD276/B7-H3HumanMammalianCellsC-HisHY-P74464-1BBL/TNFSF9MouseMammalianCellsN-HisHY-P7144CD40L/CD154/TRAPHumanE.coliTag-freeHY-P70652CD276/B7-H3HumanMammalianCellsC-HisHY-P7678BTLA/CD272HumanMammalianCellsC-HisHY-P7685BTN3A3HumanMammalianCellsC-HisHY-P70535Galectin-9HumanMammalianCellsC-HisHY-P7366HVEMHumanSf9insectCellsC-hFcHY-P70494Nectin-1HumanMammalianCellsC-HisHY-P70807PVR/CD155HumanMammalianCellsC-HisHY-P73370PD-L2RatMammalianCellsC-hFcHY-P77879VISTAHumanMammalianCellsC-hFcHY-P75610CD137/4-1BBCanineMammalianCellsC-HisHY-P7394OX40/TNFRSF4HumanMammalianCellsC-HisHY-P77457OX40Ligand/TNFSF4CynomolgusMammalianCellsN-mFcHY-P73499CD40HumanMammalianCellsC-HisHY-P73306Nectin-3HumanMammalianCellsC-HisHY-P71248PVRIGHumanMammalianCellsC-mFcHY-P76070SIRPalphaMouseMammalianCellsC-HisHY-P73121IDOHumanE.coliTag-freeHY-P76396ICOSHumanMammalianCellsC-His-hFcHY-P77575ICOSLGCynomolgusMammalianCellsC-HisHY-P72353CD28Human/CynomolgusMammalianCellsC-Fc-AviHY-P72033LIGHTHumanMammalianCellsN-hFc-MycHY-P73076GITRHumanMammalianCellsC-HisHY-P7318GITRL/AITRLHumanE.coliTag-freeHY-P72887CD200HumanMammalianCellsC-hFcHY-P76780CD200R1CynomolgusMammalianCellsC-His5www.MedChemEInhibitors ? ScreeningLibraries ? ProteinsMCE重組蛋白MCE重組蛋白產(chǎn)品種類豐富，涵蓋細(xì)胞因子、病毒蛋白、免疫檢查點蛋白、CAR-T蛋白、CD抗原、受體蛋白、生物素標(biāo)記蛋白、GMP級蛋白、酶等多種分類，可用于人、病毒、小鼠、大鼠、猴、豬、狗、牛、羊、兔、貓、非洲爪蟾等多個物種不同研究領(lǐng)域的生物學(xué)研究，包括蛋白結(jié)構(gòu)研究、免疫檢測試劑、重組蛋白藥物、診斷試劑開發(fā)、抗體藥物靶點、CAR-T細(xì)胞治療靶點、Fc受體、流感病毒蛋白和細(xì)胞因子等熱門研究領(lǐng)域。MCE因高品質(zhì)的產(chǎn)品和優(yōu)質(zhì)的售前售后服務(wù)，成為全球數(shù)百萬計的科學(xué)家和技術(shù)人員值得信賴的實驗伙伴。產(chǎn)品種類豐富： 細(xì)胞因子和生長因子、免疫檢查點蛋白、CAR-T相關(guān)蛋白、CD抗原、受體蛋白、酶&調(diào)節(jié)子、補(bǔ)體系統(tǒng)蛋白、病毒類蛋白、生物素標(biāo)記蛋白、熒光標(biāo)記蛋白、GMP級蛋白,泛素相關(guān)蛋白等產(chǎn)品物種多樣性：人、病毒、小鼠、大鼠、猴、豬、狗、牛、羊、兔、貓、非洲爪蟾、細(xì)菌、真菌等低內(nèi)毒素水平： LAL法驗證，內(nèi)毒素含量低于絕大多數(shù)供應(yīng)標(biāo)準(zhǔn)高純度： SDS和HPLC檢測驗證高生物活性： 相關(guān)體內(nèi)/體外生物學(xué)實驗測定穩(wěn)定的一致性： 多批次檢測數(shù)據(jù)確認(rèn)規(guī)格齊全： 滿足客戶的多種預(yù)分裝規(guī)格高純度ThepurityofhumanBMP-2isgreaterthan95%asanalyzedbySDSunderreducing(R)andnon-reducing(N)condition.kDa M R 120806040302010卓越的批間穩(wěn)定性TheED50ofMCEhumanVEGF165fromthreedifferentLotsaresimilar.1.0Lot1nm)0.8Lot20.6Lot3(4900.4OD0.2Net0.01010101010VEGF165,Human(ng/mL)

高活性HumanGM-CSFstimulatescellproliferationofTF-1cellswithanED50oflessthan0.5ng/mL.2.0(490nm)1.51.0NetOD0.50.010101010101010GM-CSF,Human(ng/mL)競品對比TheED50ofhumanVEGF165fromMCE’seachLotislowerthanofCompetitorP.1.0BrandPnm)0.8Lot20.6Lot3(4900.4OD0.2Net0.010-210-1101010VEGF165,Human(ng/mL)MCEMasterofBioactiveMoleculesPublicationsCitingUseofMCEProductsNature.2023Jun;618(7964):374-382.Nature.2023Jun;618(7966):862-870.Nature.2023Jun;618(7965):590-597.Nature.2023Jun;618(7963):180-187.Nature.2023May;617(7962):818-826Science.2023Jun9;380(6649):eabo2296.Science.2022Dec2;378(6623):eabo5503.Science.2022Nov18;378(6621):eabq7361.Science.2022Oct14;378(6616):eabq0132.Science.2022Jul8;377(6602):eabg9302Cell.2023Jun22;186(13):2823-2838.e20.Cell.2023May11;186(10):2144-2159.e22.Cell.2023Mar30;186(7):1352-1368.e18.Cell.2023Mar2;186(5):1026-1038.e20.Cell.2023Feb16;186(4):850-863.e16MCEGlobalPartnersMCEMasterofBioactiveMolecules客戶驗證誘導(dǎo)小鼠肺成纖維細(xì)胞纖維化TGF-β1(HY-P7117)刺激原代小鼠肺成纖維細(xì)胞，通過qRT-PCR和WB檢測PTPN13和NOX4表達(dá)水平，確定其與細(xì)胞纖維化密切相關(guān)[41]。ControlTGF-β1PTPN13NOX4expression10**expression8**86mRNA6mRNA44Relative2Relative200

ControlTGF-β1ControlTGF-β1CollagenI139kDaPTPN13310kDaα-SMA42kDaNOX455kDaGAPDH37kDaGAPDH37kDa構(gòu)建腎臟類器官從小鼠腎臟組織中提取細(xì)胞，利用微流體技術(shù)結(jié)合3D打印機(jī)制作類器官珠，輔以Noggin(HY-P7086)、R-spondin-1(HY-P7114)、FGF-4(HY-P7014)、FGF-basic(HY-P7066)、SB-431542(HY-10431)、Laduviglusib(HY-10182)培養(yǎng)，7天后，得到數(shù)千個大小、形狀和成分具有高度重復(fù)性的腎臟類器官[42]。OrganoidGeneratingKidneyOrganoidBeadsKidneyOrganoidsMatrigel+CellsDay1Day7QDs/Drugs7days24hrsOrganoidCulturingCulturingHighThroughputScreeningOil4°CKidneyOrganoidBeads200μm200μmCultureDish37°CIFN-γ誘導(dǎo)蛋白16(IFI16)的積累通過Westernblotting檢測IFN-γ(HY-P7025)處理人肺腺癌上皮(A549)細(xì)胞18小時后，蛋白16(IFI16)的積累，通過免疫染色檢測IFN-γ誘導(dǎo)16小時后IFI16的細(xì)胞定位[43]。HumanIFN-γ(ng/mL)0505001000IFI16—100(kDa)—70β-actin—40

NegativeControl IFN-γ(500ng/mL)DAPI/IFI1617www.MedChemEInhibitors ? ScreeningLibraries ? Proteins更多文獻(xiàn)引用情況文獻(xiàn)產(chǎn)品名稱貨號AdvFunctMater.10March2022.IFN-gamma;IL-13;IL-4HY-P7071;HY-P7076A;HY-P7080SignalTransductTargetTher.2022Mar11;7(1):83.AXLHY-P7622SignalTransductTargetTher.2022Jan7;7(1):6.HABP2HY-P70832NatMicrobiol.2021Jul;6(7):932-945.IFN-gammaHY-P7025AdvSci(Weinh).2021Dec;8(24):e2100808.NPYHY-P71063CellDeathDiffer.2022Apr;29(4):818-831.FGFbasic;FGF-2HY-P7004;HY-P7066NatCommun.2022Feb23;13(1):1017.TGFbeta1HY-P7118JImmunotherCancer.2022Feb;10(2):e003716.IL-2HY-P7077Small.2020Jun;16(22):e2001371.FGF-4;FGF-2;Noggin;RSPO1HY-P7014;HY-P7066;HY-P7086;HY-P7114Biomaterials.2021Jan;265:120392.GM-CSFHY-P7069RedoxBiol.2021Jul;43:101994.IL-6HY-P7103ATheranostics.2022Jan1;12(3):1097-1116.IGF2HY-P7019Theranostics.2022Jan1;12(2):747-766.IFN-gammaHY-P7025;HY-P7071Theranostics.2021May13;11(14):7110-7125.TGFbeta1HY-P7118Theranostics.2021Jan9;11(7):3244-3261.TGFbeta1HY-P7117ActaPharmSinB.2020Sep;10(9):1619-1633.M-CSFHY-P7085JExpClinCancerRes.2020Jun23;39(1):119.IL-6RalphaHY-P7223BiosensBioelectron.2020Sep19;173:112619.IFN-gammaHY-P7025CardiovascDiabetol.2022Feb15;21(1):25.AsprosinHY-P7612JControlRelease.IL-4;M-CSF;TNF-alpha;HY-P7080;HY-P7085;HY-P7090;2021Jul26;S0168-3659(21)00383-7.MIP-1alpha;GM-CSFHY-P7255;HY-P7361CellRep.2022Feb1;38(5):110319.TNFalpha;GMPIL-6HY-P70426;HY-P7044GCellRep.2021Jan5;34(1):108576.IL-1RAHY-P7029ACellRep.2020Jan7;30(1):98-111.e5.FGFbasic;EGF;VEGF121HY-P7004;HY-P7109;HY-P7420ActaBiomater.2020Jan1;101:152-167.DKK-1HY-P7155ACancerLett.2022Mar9;215629.BDNFHY-P7116ACancerLett.13July2021.FGFbasicHY-P7004CellDeathDis.2021Apr14;12(4):397.NRG1-beta1HY-P7365CellDeathDis.2021Nov27;12(12):1113.FGFbasicHY-P7004CellDeathDis.2021Oct12;12(10):934.M-CSFHY-P7085CellDeathDis.2020May7;11(5):323.TNF-alphaHY-P7416CellDeathDis.2020Nov4;11(11):950.Insulin;FGFbasic;EGFHY-P0035;HY-P7004;HY-P7109JNeuroinflammation.2019Nov26;16(1):234.IL-1RAHY-P702918MCEMasterofBioactiveMoleculesReferences:Jun-MingZhang.Cytokines,inflammation,andpain.IntAnesthesiolClin.2007Spring;45(2):27-37.PedroBerraondo,etal.Cytokinesinclinicalcancerimmunotherapy.BrJCancer.2019Jan;120(1):6-15.Ferreira,Vinicius,etal.CytokinesandInterferons:TypesandFunctions.InAutoantibodiesandCytokines,editedbyWahidKhan.London:IntechOpen,2018.XiaochenRen,etal.GrowthFactorEngineeringStrategiesforRegenerativeMedicineApplications.FrontBioengBiotechnol.2019;7:469.StoneWL,LeavittL,VaracalloM.Physiology,GrowthFactor.In:StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2022Jan.OzlemGuzeloglu-Kayisli,HughSTaylor,etal.Theroleofgrowthfactorsandcytokinesduringimplantation:endocrineandparacrineinteractions.SeminReprodMed.2009Jan;27(1):62-79.YapingZhang,etal.FunctionsofImmuneCheckpointMoleculesBeyondImmuneEvasion.AdvExpMedBiol.2020;1248:201-226.XingHe,etal.Immunecheckpointsignalingandcancerimmunotherapy.CellResearch.2020;30:660-669.Marin-AcevedoJA,etal.Nextgenerationofimmunecheckpointtherapyincancer:newdevelopmentsandchallenges.JHematolOncol.2018;11(1):39.ChristopherDeRenzo,etal.GeneticModificationStrategiestoEnhanceCARTCellPersistenceforPatientsWithSolidTumors.FrontImmunol.2019Feb15;10:218.MEssand,etal.GeneticallyengineeredTcellsforthetreatmentofcancer.JInternMed.2013Feb;273(2):166-81.ZhenguangWang,etal.NewdevelopmentinCAR-Tcelltherapy.JHematolOncol.2017;10:53.LekhaMikkilineni,etal.ChimericantigenreceptorT-celltherapiesformultiplemyeloma.Blood.2017Dec14;130(24):2594-2602.JuliusM.Cruse,RobertE.Lewis,andHuanWang.CLUSTEROFDIFFERENTIATION(CD)ANTIGENS.ImmunologyGuidebook.2004:47-124.TomasKalina,etal.CDMaps-DynamicProfilingofCD1-CD100SurfaceExpressiononHumanLeukocyteand[16]LymphocyteSubsets.FrontImmunol.2019Oct23;10:2434.DarioGosmann,AngelaM.Krackhardt,CalogeroD’Alessandria,etal.P.romiseandchallengesofclinicalnon-invasiveT-celltrackingintheeraofcancerimmunotherapy.EJNMMIRes.2022Jan31;12(1):5.MareeS.etal.FcReceptors.AdvExpMedBiol.2008;640:22-34.SanaeBenMkaddem,etal.UnderstandingFcReceptorInvolvementinInflammatoryDiseases:FromMechanismstoNewTherapeuticTools.FrontImmunol.2019Apr12;10:811.D.Mancardi.FcReceptor-DependentImmunity.ReferenceModuleinBiomedicalSciences.2014:B978-0-12-801238-3.00119-7.M?rtensson,A.DevelopmentofanAntigen-independentAffinityAssaytoStudytheBindingofIgGtoFcGammaReceptors.2012.S.Xiong,etal.HumanImmuneSystem,Editor(s):Andersrahme,ComprehensiveBiomedicalPhysics,Elsevier,2014,Pages91-114.Carl-HenrikHeldin,etal.SignalsandReceptors.ColdSpringHarbPerspectBiol.2016Apr;8(4):a005900.RitaSantos,etal.Acomprehensivemapofmoleculardrugtargets.NatRevDrugDiscov.2017Jan;16(1):19-34..

Young-SunLee,etal.Anti-InflammatoryEffectsofGLP-1-BasedTherapiesbeyondGlucoseControl.MediatorsInflamm.2016;2016:3094642.PeterK.etal.Enzymes:principlesandbiotechnologicalapplications.EssaysBiochem.2015Nov15;59:1-41.AntonioBlanco,etal.Enzymes,Editor(s):AntonioBlanco,Gustavolanco,MedicalBiochemistry,AcademicPress,2017,Pages153-175.CooperGM.TheCell:AMolecularApproach.2ndedition.Sunderland(MA):SinauerAssociates;2000.LiubovPoshyvailo.Modellingandsimulationsofenzyme-catalyzedreactions.NationalUniversityof“Kyiv-MohylaAcademy”FacultyofNaturalSciences,DepartmentofPhysicsandMathematics.2015.JanewayCAJr,etal.Thecomplementsystemandinnateimmunity.Immunobiology:TheImmuneSysteminHealthandDisease.5thedition.NewYork:GarlandScience;2001.GuillerminaGirardi,etal.EssentialRoleofComplementinPregnancy:FromImplantationtoParturitionandBeyond.FrontImmunol.2020;11:1681.LanKNguyen,etal.Whenubiquitinationmeetsphosphorylation:asystemsbiologyperspectiveofEGFR/MAPKsignaling.CellCommunSignal.2013Jul31;11:52.GuoHJ,etal.Biochemistry,Ubiquitination.In:StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2022Jan.FuShang,etal.Ubiquitin-proteasomepathwayandcellularresponsestooxidativestress.FreeRadicBiolMed.2011Jul1;51(1):5-16.Hochstrasser,M.Originandfunctionofubiquitin-likeproteins.Nature.2009Mar26;458(7237):422-9.ViralStructuralProteins.NCBI.Literature.MeSHDatabase.Yearintroduced:1990.JenniferLouten.VirusStructureandClassification.EssentialHumanVirology.2016:19-29.GelderblomHR.StructureandClassificationofViruses.In:BaronS,editor.MedicalMicrobiology.4thedition.Galveston(TX):UniversityofTexasMedicalBranchatGalveston;1996.Chapter41.Chand